Researchers have reported early clinical findings evaluating a stem cell therapy derived from human exfoliated deciduous teeth (SHED) as a potential treatment for children with cerebral palsy. The study assessed the safety and potential functional effects of administering these cells to pediatric patients with the neurological condition.
Cerebral palsy affects approximately two to three children per 1,000 live births worldwide and is caused by early brain injury that disrupts normal movement and posture. Current treatment options focus primarily on rehabilitation, physical therapy, and symptom management rather than addressing the underlying neurological damage.
In the study, investigators used stem cells isolated from naturally shed deciduous (baby) teeth. These cells are a type of mesenchymal stem cell found in dental pulp and can differentiate into several cell types. Because baby teeth are shed naturally, SHED cells can be collected noninvasively and expanded in laboratory culture, making them a potential source of cells for regenerative therapies.
The clinical investigation involved children with cerebral palsy who received SHED-based therapy under controlled conditions. Stem cells derived from donor deciduous teeth were prepared and administered to patients, who were then monitored over time for safety and functional outcomes.
According to the researchers, the treatment was generally well tolerated. No serious adverse events linked to the stem cell administration were reported during the study period. The investigators also observed improvements in some motor and functional assessments among certain participants following treatment. However, the authors noted that the study design does not allow firm conclusions about treatment effectiveness.
The researchers suggest that SHED cells may have therapeutic potential because of their neurotrophic and immunomodulatory properties. These characteristics may support neuronal repair or reduce inflammation associated with brain injury. Previous preclinical studies have indicated that these mechanisms could contribute to functional improvements in neurological disorders.
The study also highlights practical advantages of dental pulp–derived stem cells as a potential therapeutic source. Because they can be obtained from naturally shed teeth and expanded in culture, SHED cells may offer a relatively accessible and scalable cell source for regenerative medicine applications.
The authors note that additional research will be needed to determine the long-term safety and clinical effectiveness of SHED-based therapies. Larger controlled trials will be required to confirm whether the treatment can produce consistent functional improvements in patients with cerebral palsy.